Serum anti-TOPO48 autoantibody as a biomarker for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Chen, 2016, Cancer statistics in China, 2015, CA Cancer J Clin, 66, 115, 10.3322/caac.21338 Wang, 2014, Epidemiological studies of esophageal cancer in the era of genome-wide association studies, World J Gastrointest Pathophysiol, 5, 335, 10.4291/wjgp.v5.i3.335 Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516 Ro, 2015, Value of screening endoscopy in evaluation of esophageal, gastric and colon cancers, World J Gastroenterol, 21, 9693, 10.3748/wjg.v21.i33.9693 Shimada, 2003, Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma, Surgery, 133, 486, 10.1067/msy.2003.139 Shimada, 2003, Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma, J Am Coll Surg, 196, 573, 10.1016/S1072-7515(02)01905-1 Takikita, 2009, Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma, BMC Cancer, 9, 310, 10.1186/1471-2407-9-310 Kosugi, 2004, Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients, World J Surg, 28, 680, 10.1007/s00268-004-6865-y Tan, 2009, Serum autoantibodies as biomarkers for early cancer detection, Febs J, 276, 6880, 10.1111/j.1742-4658.2009.07396.x Chen, 2017, Tumor-associated autoantibodies against Fascin as a novel diagnostic biomarker for esophageal squamous cell carcinoma, Clin Res Hepatol Gastroenterol, 41, 327, 10.1016/j.clinre.2016.10.011 Peng, 2016, Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma, Cancer Med, 5, 1388, 10.1002/cam4.702 Ren, 2013, Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma, Oncol Rep, 30, 2297, 10.3892/or.2013.2714 Ye, 2013, Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma, Tumour Biol, 34, 1873, 10.1007/s13277-013-0729-8 Zhang, 2012, Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma, Biomarkers, 17, 372, 10.3109/1354750X.2012.680609 Zhou, 2011, Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma, World J Gastroenterol, 17, 1373, 10.3748/wjg.v17.i10.1373 Yie, 2016, A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma, Br J Cancer, 115, 1555, 10.1038/bjc.2016.369 Watanable, 1990 Sobin, 2002 Mealy, 1996, Tumour marker detection in oesophageal carcinoma, Eur J Surg Oncol, 22, 505, 10.1016/S0748-7983(96)92998-4 Reuschenbach, 2009, A systematic review of humoral immune responses against tumor antigens, Cancer Immunol Immunother, 58, 1535, 10.1007/s00262-009-0733-4 Cao, 2012, Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma, J Transl Med, 10, 197, 10.1186/1479-5876-10-197 Zhang, 2015, Serum autoantibodies in the early detection of esophageal cancer: a systematic review, Tumour Biol, 36, 95, 10.1007/s13277-014-2878-9 Zhou, 2014, Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma, Dis Esophagus, 27, 790, 10.1111/dote.12145 Chen, 2004, Serum markers as predictors of esophageal squamous dysplasia and early cancer, Anticancer Res, 24, 3245 Ralhan, 2000, Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India, Int J Cancer, 85, 791, 10.1002/(SICI)1097-0215(20000315)85:6<791::AID-IJC9>3.0.CO;2-K Chai, 2014, Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma, Scand J Immunol, 80, 362, 10.1111/sji.12202 Xu, 2014, Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma, Am J Gastroenterol, 109, 36, 10.1038/ajg.2013.384 Looi, 2006, Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies, Oncol Rep, 16, 1105 Shimada, 2000, Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma, Cancer, 89, 1677, 10.1002/1097-0142(20001015)89:8<1677::AID-CNCR5>3.0.CO;2-9 Shimada, 2007, Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma, Int J Oncol, 30, 97 Zaenker, 2013, Serologic autoantibodies as diagnostic cancer biomarkers—a review, Cancer Epidemiol Biomarkers Prev, 22, 2161, 10.1158/1055-9965.EPI-13-0621 Dong, 2010, Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma, J Transl Med, 8, 81, 10.1186/1479-5876-8-81 Liu, 2010, Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma, BMC Cancer, 10, 467, 10.1186/1471-2407-10-467 Kobold, 2010, Prognostic and diagnostic value of spontaneous tumor-related antibodies, Clin Dev Immunol, 2010, 721531, 10.1155/2010/721531 Heo, 2012, Tumor-associated autoantibodies as diagnostic and prognostic biomarkers, BMB Rep, 45, 677, 10.5483/BMBRep.2012.45.12.236 Zaenker, 2016, Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients, Autoimmun Rev, 15, 477, 10.1016/j.autrev.2016.01.017 Carter, 2001, Improving the efficacy of antibody-based cancer therapies, Nat Rev Cancer, 1, 118, 10.1038/35101072